Judo Bio, a biotechnology company pioneering oligonucleotide medicines delivered to the kidney, today announced that the company will present mechanistic and preclinical data that demonstrate the use ...
Newly launched Judo Bio aims to develop ligand-siRNA conjugates through its Selectively Targeting RNA Into KidnEy (STRIKE) ...
Taking the mat is Judo Bio, an up-and-coming biotech armed with $100 million to develop oligonucleotide medicines targeting ...
Japan's judo governing body decided on the first female head coach of its women's national team Wednesday, more than 10 years ...
On the fourth day of the 2024 World Junior Judo Championship, crowds from all around the world gather in the capital of ...
NorthernIrelandWorld on MSN7h
European medal success for Coleraine's Kyokan Judo Club in BelgiumA Coleraine judo club has recently returned from a championship in Belgium with an array of medals after competing against ...
The Cambridge, Massachusetts-based biotech is using what it calls ligand-siRNA conjugates to reach drug targets in the kidney, which historically have been difficult to reach with RNA therapies.
Judo Bio, a biotechnology company pioneering oligonucleotide medicines delivered to the kidney, today announced the company’s launch and $100 million in initial financing, including seed financing and ...
Tributes have been paid to a former international judo competitor and coach who shared his love of judo with hundreds of ...
Wales' most successful judoka, Natalie Powell, brings an end to a career which saw her win medals at every major championship ...
Judo athletes from around the world convened in San Jose on Saturday to remember the life of legendary San Jose State ...
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback